Clinical trials: Patients With Cancer
Melanoma Stage III or IV
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As such they are currently used in clinical vaccination protocols in cancer patients, and both immunological and clinical responses have…
- Trial name
- NCT00243594
- Testing
- Peptide-pulsed dendritic cells
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Neoplasms
A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.
This study will evaluate the pharmacokinetics, maximum tolerated dose and anti-tumor activity of RO5083945 in patients with metastatic and/or locally advanced malignant EGFR+ solid tumors.
- Trial name
- NCT00721266
- Testing
- RO5083945
- Where
- 5 sites in France, Spain
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of ERW316 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Trial name
- NCT07570966
- Testing
- ERW316, Fulvestrant, Letrozole
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
This is a multi-center, open-label, phase II, single-arm trial evaluating combination of darolutamide and high testosterone doses - extreme bipolar androgen therapy (ExBAT) - in patients with metastatic castration-resistant…
- Trial name
- ExBAT (NCT04558866)
- Testing
- Testosterone Cypionate, Darolutamide
- Where
- 6 sites in Brazil
- Volunteers
- 51 people
- Sponsor
- Latin American Cooperative Oncology Group
Breast Cancer
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
PREcoopERA is a randomized (2:2:1), multicenter, open-label, three-arm (A, B, C), Window-of-Opportunity (WOO) trial to evaluate the activity and safety of giredestrant (A) versus giredestrant plus triptorelin (B) versus…
- Trial name
- PREcoopERA (NCT05896566)
- Testing
- Giredestrant, Triptorelin, Anastrozole
- Where
- 37 sites in France, Germany and 4 more
- Volunteers
- 231 people
- Sponsor
- ETOP IBCSG Partners Foundation
Adjuvant Chemotherapy, Ovarian Neoplasms
Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
This study is a multicenter, open-label, randomized clinical trial. Patients with ovarian cancer receiving postoperative adjuvant chemotherapy were eligible to enroll in this study.
- Conditions
- Adjuvant Chemotherapy, Ovarian Neoplasms, Ovarian Cancer
- Trial name
- NCT03858166
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Shandong University
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Endometrial Cancer
Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of letrozole in treating women who have recurrent or…
- Trial name
- NCT00004251
- Testing
- letrozole
- Volunteers
- 33 people
- Sponsor
- NCIC Clinical Trials Group
Epithelial Ovarian Cancer, Relapse
Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse
Assessing the safety and efficacy of the bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patient with high grade serous or high grade endometrioid or other high grade epithelial non mucinous ovarian tumor, with at…
- Trial name
- BOLD (NCT04015739)
- Testing
- Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination
- Where
- 9 sites in France
- Volunteers
- 74 people
- Sponsor
- ARCAGY/ GINECO GROUP
Ovarian Cancer
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
This is a multicenter, open-label study of safety and efficacy of Quisinostat in combination with Paclitaxel + Carboplatin chemotherapy in patients with metastatic or locally advanced epithelial ovarian cancer, primarily…
- Trial name
- NCT02948075
- Testing
- Quisinostat, Paclitaxel, Carboplatin
- Where
- 6 sites in Russia
- Volunteers
- 31 people
- Sponsor
- NewVac LLC
Myelodysplastic Syndrome, Acute Myeloid Leukemia
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
This is a non-blinded, non-randomized pharmacokinetic study to determine the oral bioavailability of clofarabine, and the effect of cimetidine on clofarabine pharmacokinetics in patients with poor-risk acute leukemias and…
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT01169012
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lymphoma, Precancerous/Nonmalignant Condition
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
RATIONALE: Human T-cell lymphotropic virus type 1 (HTLV-1) can cause cancer. Zidovudine is an antiviral drug that acts against the human T-cell lymphotropic virus type 1.
- Trial name
- NCT00854581
- Testing
- PEG-interferon alfa-2b, Interferon alfa-2b, Valproic Acid
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Miami
Advanced Melanoma, Non-small Cell Lung Cancer
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
This trial is a phase 1/1b study to evaluate the safety, efficacy, and tolerability of APX005M in combination with nivolumab and cabiralizumab.
- Conditions
- Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03502330
- Testing
- APX005M, Cabiralizumab, Nivolumab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Yale University
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00056030
- Testing
- cetuximab, fluorouracil, leucovorin calcium
- Where
- 162 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Nonsmall Cell Lung Cancer
Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer
This study will treat patients with advanced NSCLC who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may…
- Trial name
- JACKPOT1 (NCT03450330)
- Testing
- AZD4205
- Where
- 4 sites in Australia
- Volunteers
- 10 people
- Sponsor
- Dizal Pharmaceuticals
Relapsed and Refractory Multiple Myeloma (RRMM)
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Primary Objective: 1. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after…
- Trial name
- NCT05673967
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Soft Tissue Sarcoma
The Effects of Observer Presence and Type on Patients' Perception of Exercise in Patients With Soft Tissue Sarcoma
The primary aim of the study is to investigate the effects of supervised exercise, telerehabilitation and home-based exercise on patient perception in patients with soft tissue sarcoma.
- Trial name
- NCT05596565
- Testing
- Supervised Exercise by a physiotherapist via face to face
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul Medeniyet University
Gallbladder Cancer, Liver Cancer
Quality Of Life in Patients With Malignant Biliary Obstruction
You may have symptoms like itching, abdominal pain, loss of appetite, fatigue, fevers and chills. The treatment you will receive to relieve the blockage is also intended to relieve symptoms and improve your quality of life.
- Conditions
- Gallbladder Cancer, Liver Cancer, Bile Duct Cancer
- Trial name
- NCT00579865
- Testing
- questionnaires
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Primary Objective: To demonstrate the superiority of cabazitaxel plus prednisone at 25 mg/m^2 (Arm A) or 20 mg/m^2 (Arm B) versus docetaxel plus prednisone (Arm C) in term of overall survival (OS) in participants with metastatic…
- Trial name
- FIRSTANA (NCT01308567)
- Testing
- Cabazitaxel (XRP6258), Docetaxel (XRP6976), Prednisone
- Where
- 167 sites in United States, Australia and 23 more
- Volunteers
- 1,168 people
- Sponsor
- Sanofi
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.